In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical validation and regulatory approval.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.